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Introduction: Haemorrhagic shock (HS) is one of the most common types of shock 
and occurs due to uncontrollable bleeding, often resulting in organ ischaemia, tissue 
hypoperfusion and organ injury (1). Restoration of blood flow and reoxygenation is 
associated with an exacerbation of tissue injury and an excessive inflammatory 
response (2). Many drugs (or interventions) that have reduced inflammation and organ 
injury in HS attenuate the activation of nuclear factor kappa B (NF-κB), which 
controls the transcription of several proinflammatory proteins (3). Thus, the aim of the 
present work is to investigate the effects of a specific and potent inhibitor of IκB 
kinase, which plays a pivotal role in the activation of NF-κB complex, in the organ 
dysfunction associated with HS. 
Methods: Male Wistar rats were subjected to HS under sodium thiopentone 
anesthesia (120 mg/kg; i.p.). Specifically, blood was removed from the carotid artery 
in order to reduce mean arterial pressure to 30 ± 2 mmHg for 90 min. This was 
followed by resuscitation with the shed blood over 5 min. Rats were treated with the 
inhibitor of IκB kinase (IKK16; 1 mg/kg; i.v.) or vehicle (10% DMSO) on 
resuscitation. At 4 h after resuscitation, blood was removed to measure the following 
indicators of organ injury: Creatinine (renal dysfunction), lactate (tissue ischaemia), 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (liver injury). 
Creatinine was also measured in urine to calculate creatinine clearance. 
Myeloperoxidase (MPO) activity was measured in the lung as an indicator of 
neutrophil recruitment. In addition, organs were removed for Western blot analysis of 
signaling events that lead to the activation of NF-κB. Data was analyzed by one or 
two-way ANOVA followed by Bonferroni’s post hoc test for multiple comparisons. P 
< 0.05 was considered significant. 
Results: When compared to sham-operated rats (n=8), HS resulted in a significant 
decrease in creatinine clearance (from 1.4 ± 0.09 to 0.12 ± 0.03 mL/min) as well as 
rises in serum creatinine (from 33.5 ± 1.7 to 108.8 ± 5.6 umol/L), AST (from 146.4 ± 
23.7 to 1138.0 ± 114.1 U/L), ALT (from 50.0 ± 4.1 to 347.6 ± 44.6 U/L) and lactate 
(from 1.0 ± 0.15 to 3.4 ± 0.6 mmol/L) (n=10; p<0.05 for all parameters measured), 
indicating the development of renal dysfunction, liver injury and organ ischaemia. HS 
also resulted in a significant increase in lung MPO activity (from 30.6 ± 9.3 to 93.3 ± 
4.7 U/tissue g; n=4; p<0.05), indicating the development of lung inflammation. 
Western blot analysis of kidney and liver tissue from HS rats revealed increases in 
phosphorylation of IκB, nuclear translocation of NF-κB subunit p65, increases in 
phosphorylation of ERK 1/2 and enhanced expression of inducible nitric oxide 
synthase (iNOS). Treatment of HS-rats with IKK16 protected animals against the 
organ injury and dysfunction induced by HS. In addition, IKK16 attenuated 
phosphorylation of IκB and nuclear translocation of NF-κB subunit p65, indicating 
that this molecule does indeed prevent the activation of NF-κB caused by HS. 
Surprisingly, IKK16 also caused an increase in the phosphorylation of Akt; and 
activation of the Akt-survival pathway may well contribute to the observed beneficial 
effects of IKK16. 
Conclusion: In conclusion, administration of IKK16 on resuscitation attenuated the 
organ dysfunction associated with HS. This effect may be (at least in part) due to the 
observed inhibition of NF-κB and/or the activation of the Akt-survival pathway. 
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